Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation
dc.contributor.author | Johnston, A. | en_US |
dc.contributor.author | Arnadottir, S. | en_US |
dc.contributor.author | Gudjonsson, Johann E. | en_US |
dc.contributor.author | Aphale, A. | en_US |
dc.contributor.author | Sigmarsdottir, A. A. | en_US |
dc.contributor.author | Gunnarsson, S. I. | en_US |
dc.contributor.author | Steinsson, J. T. | en_US |
dc.contributor.author | Elder, J. T. | en_US |
dc.contributor.author | Valdimarsson, H. | en_US |
dc.date.accessioned | 2010-06-01T18:57:40Z | |
dc.date.available | 2010-06-01T18:57:40Z | |
dc.date.issued | 2008-08 | en_US |
dc.identifier.citation | Johnston, A.; Arnadottir, S.; Gudjonsson, J.E.; Aphale, A.; Sigmarsdottir, A.A.; Gunnarsson, S.I.; Steinsson, J.T.; Elder, J.T.; Valdimarsson, H. (2008). "Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation." British Journal of Dermatology 159(2): 342-350. <http://hdl.handle.net/2027.42/72152> | en_US |
dc.identifier.issn | 0007-0963 | en_US |
dc.identifier.issn | 1365-2133 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/72152 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18547319&dopt=citation | en_US |
dc.format.extent | 747142 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.rights | Journal Compilation © 2008 British Association of Dermatologists | en_US |
dc.subject.other | Cytokines | en_US |
dc.subject.other | Leptin | en_US |
dc.subject.other | Obesity | en_US |
dc.subject.other | Psoriasis | en_US |
dc.subject.other | Resistin | en_US |
dc.subject.other | UVB | en_US |
dc.title | Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Dermatology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | † Department of Dermatology, University of Michigan Medical Center, Ann Arbor, MI, U.S.A | en_US |
dc.contributor.affiliationother | * Department of Immunology, Landspitali University Hospital, Reykjavik, Iceland | en_US |
dc.contributor.affiliationother | † Department of Medicine, University of Iceland, Reykjavik, Iceland | en_US |
dc.contributor.affiliationother | § Blue Lagoon Dermatological Clinic, Grindavik, Iceland | en_US |
dc.contributor.affiliationother | ¶ Ann Arbor Veterans Affairs Health System, Ann Arbor, MI, U.S.A | en_US |
dc.identifier.pmid | 18547319 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/72152/1/j.1365-2133.2008.08655.x.pdf | |
dc.identifier.doi | 10.1111/j.1365-2133.2008.08655.x | en_US |
dc.identifier.source | British Journal of Dermatology | en_US |
dc.identifier.citedreference | Christophers E. Psoriasis – epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314 – 20. | en_US |
dc.identifier.citedreference | Griffiths CE, Christophers E, Barker JN et al. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol 2007; 156: 258 – 62. | en_US |
dc.identifier.citedreference | Valdimarsson H. The genetic basis of psoriasis. Clin Dermatol 2007; 23: 563 – 7. | en_US |
dc.identifier.citedreference | Nair RP, Stuart PE, Nistor I et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 2006; 78: 827 – 51. | en_US |
dc.identifier.citedreference | Valdimarsson H, Baker BS, Jonsdottir I et al. Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol Today 1995; 16: 145 – 9. | en_US |
dc.identifier.citedreference | Telfer NR, Chalmers RJ, Whale K et al. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol 1992; 128: 39 – 42. | en_US |
dc.identifier.citedreference | Gudjonsson JE, Thorarinsson AM, Sigurgeirsson B et al. Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a prospective study. Br J Dermatol 2003; 149: 530 – 4. | en_US |
dc.identifier.citedreference | Naldi L, Chatenoud L, Linder D et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case–control study. J Invest Dermatol 2005; 125: 61 – 7. | en_US |
dc.identifier.citedreference | Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32: 982 – 6. | en_US |
dc.identifier.citedreference | Raychaudhuri SP, Gross J. Psoriasis risk factors: role of lifestyle practices. Cutis 2000; 66: 348 – 52. | en_US |
dc.identifier.citedreference | Marino MG, Carboni I, De Felice C et al. Risk factors for psoriasis: a retrospective study on 501 outpatients clinical records. Ann Ig 2004; 16: 753 – 8. | en_US |
dc.identifier.citedreference | Neimann AL, Shin DB, Wang X et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829 – 35. | en_US |
dc.identifier.citedreference | Sommer DM, Jenisch S, Suchan M et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298: 321 – 8. | en_US |
dc.identifier.citedreference | Rucevic I, Perl A, Barisic-Drusko V et al. The role of the low energy diet in psoriasis vulgaris treatment. Coll Antropol 2003; 27: 41 – 8. | en_US |
dc.identifier.citedreference | Higa-Sansone G, Szomstein S, Soto F et al. Psoriasis remission after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Obes Surg 2004; 14: 1132 – 4. | en_US |
dc.identifier.citedreference | Herron MD, Hinckley M, Hoffman MS et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005; 141: 1527 – 34. | en_US |
dc.identifier.citedreference | Sterry W, Strober BE, Menter A. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007; 157: 649 – 55. | en_US |
dc.identifier.citedreference | Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000; 11: 327 – 32. | en_US |
dc.identifier.citedreference | Curat CA, Wegner V, Sengenes C et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006; 49: 744 – 7. | en_US |
dc.identifier.citedreference | Kanda H, Tateya S, Tamori Y et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006; 116: 1494 – 505. | en_US |
dc.identifier.citedreference | Fain JN, Madan AK, Hiler ML et al. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004; 145: 2273 – 82. | en_US |
dc.identifier.citedreference | Bruun JM, Lihn AS, Madan AK et al. Higher production of IL-8 in visceral vs. subcutaneous adipose tissue. Implication of nonadipose cells in adipose tissue. Am J Physiol Endocrinol Metab 2004; 286: E8 – 13. | en_US |
dc.identifier.citedreference | Gearing AJ, Fincham NJ, Bird CR et al. Cytokines in skin lesions of psoriasis. Cytokine 1990; 2: 68 – 75. | en_US |
dc.identifier.citedreference | Bonifati C, Carducci M, Cordiali Fei P et al. Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients – relationships with disease severity. Clin Exp Dermatol 1994; 19: 383 – 7. | en_US |
dc.identifier.citedreference | Gudjonsson JE, Johnston A, Sigmundsdottir H et al. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2004; 135: 1 – 8. | en_US |
dc.identifier.citedreference | Muoio DM, Lynis Dohm G. Peripheral metabolic actions of leptin. Best Pract Res Clin Endocrinol Metab 2002; 16: 653 – 66. | en_US |
dc.identifier.citedreference | Pelleymounter MA, Cullen MJ, Baker MB et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995; 269: 540 – 3. | en_US |
dc.identifier.citedreference | Lord GM, Matarese G, Howard JK et al. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 1998; 394: 897 – 901. | en_US |
dc.identifier.citedreference | Palacio A, Lopez M, Perez-Bravo F et al. Leptin levels are associated with immune response in malnourished infants. J Clin Endocrinol Metab 2002; 87: 3040 – 6. | en_US |
dc.identifier.citedreference | Farooqi IS, Matarese G, Lord GM et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002; 110: 1093 – 103. | en_US |
dc.identifier.citedreference | Ferraroni NR, Geloneze B, Mansour E et al. Severe hypoleptinaemia associated with insulin resistance in patients with common variable immunodeficiency. Clin Endocrinol (Oxf) 2005; 63: 63 – 5. | en_US |
dc.identifier.citedreference | Goldberg AC, Eliaschewitz FG, Montor WR et al. Exogenous leptin restores in vitro T cell proliferation and cytokine synthesis in patients with common variable immunodeficiency syndrome. Clin Immunol 2005; 114: 147 – 53. | en_US |
dc.identifier.citedreference | Matarese G, Di Giacomo A, Sanna V et al. Requirement for leptin in the induction and progression of autoimmune encephalomyelitis. J Immunol 2001; 166: 5909 – 16. | en_US |
dc.identifier.citedreference | De Rosa V, Procaccini C, Cali G et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity 2007; 26: 241 – 55. | en_US |
dc.identifier.citedreference | Loffreda S, Yang SQ, Lin HZ et al. Leptin regulates proinflammatory immune responses. FASEB J 1998; 12: 57 – 65. | en_US |
dc.identifier.citedreference | Zarkesh-Esfahani H, Pockley G, Metcalfe RA et al. High-dose leptin activates human leukocytes via receptor expression on monocytes. J Immunol 2001; 167: 4593 – 9. | en_US |
dc.identifier.citedreference | Mattioli B, Straface E, Quaranta MG et al. Leptin promotes differentiation and survival of human dendritic cells and licenses them for Th1 priming. J Immunol 2005; 174: 6820 – 8. | en_US |
dc.identifier.citedreference | Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307 – 12. | en_US |
dc.identifier.citedreference | Nagaev I, Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 2001; 285: 561 – 4. | en_US |
dc.identifier.citedreference | Savage DB, Sewter CP, Klenk ES et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001; 50: 2199 – 202. | en_US |
dc.identifier.citedreference | Utzschneider KM, Carr DB, Tong J et al. Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia 2005; 48: 2330 – 3. | en_US |
dc.identifier.citedreference | Kaser S, Kaser A, Sandhofer A et al. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 2003; 309: 286 – 90. | en_US |
dc.identifier.citedreference | Bokarewa M, Nagaev I, Dahlberg L et al. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005; 174: 5789 – 95. | en_US |
dc.identifier.citedreference | Patel L, Buckels AC, Kinghorn IJ et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003; 300: 472 – 6. | en_US |
dc.identifier.citedreference | Lehrke M, Reilly MP, Millington SC et al. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 2004; 1: e45. | en_US |
dc.identifier.citedreference | Silswal N, Singh AK, Aruna B et al. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun 2005; 334: 1092 – 101. | en_US |
dc.identifier.citedreference | Fredriksson T, Pettersson U. Severe psoriasis – oral therapy with a new retinoid. Dermatologica 1978; 157: 238 – 44. | en_US |
dc.identifier.citedreference | Corbetta S, Angioni R, Cattaneo A et al. Effects of retinoid therapy on insulin sensitivity, lipid profile and circulating adipocytokines. Eur J Endocrinol 2006; 154: 83 – 6. | en_US |
dc.identifier.citedreference | Boehncke S, Thaci D, Beschmann H et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007; 157: 1249 – 51. | en_US |
dc.identifier.citedreference | Verma S, Li SH, Wang CH et al. Resistin promotes endothelial cell activation: further evidence of adipokine–endothelial interaction. Circulation 2003; 108: 736 – 40. | en_US |
dc.identifier.citedreference | Mu H, Ohashi R, Yan S et al. Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovasc Res 2006; 70: 146 – 57. | en_US |
dc.identifier.citedreference | Cook PW, Mattox PA, Keeble WW et al. A heparin sulfate-regulated human keratinocyte autocrine factor is similar or identical to amphiregulin. Mol Cell Biol 1991; 11: 2547 – 57. | en_US |
dc.identifier.citedreference | Zheng Y, Danilenko DM, Valdez P et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007; 445: 648 – 51. | en_US |
dc.identifier.citedreference | Stallmeyer B, Kampfer H, Podda M et al. A novel keratinocyte mitogen: regulation of leptin and its functional receptor in skin repair. J Invest Dermatol 2001; 117: 98 – 105. | en_US |
dc.identifier.citedreference | Frank S, Stallmeyer B, Kampfer H et al. Leptin enhances wound re-epithelialization and constitutes a direct function of leptin in skin repair. J Clin Invest 2000; 106: 501 – 9. | en_US |
dc.identifier.citedreference | Rennekampff HO, Hansbrough JF, Kiessig V et al. Bioactive interleukin-8 is expressed in wounds and enhances wound healing. J Surg Res 2000; 93: 41 – 54. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.